Additional Supporting Information may be found in the online version of this article.

IJC_26064_sm_suppinfoFigureS1.tif8228KSupporting Information Figure 1
IJC_26064_sm_suppinfoFigureS2.tif6602KSupporting Information Figure 2
IJC_26064_sm_suppinfoFigureS3.tif2800KSupporting Information Figure 3
IJC_26064_sm_suppinfoFigureS4.tif4351KSupporting Information Figure 4
IJC_26064_sm_suppinfotableS1.doc151KSupporting Information Table S1 - MiRNAs differentially expressed in prostate cancer. 20 matched pairs of microdissected tissue samples of prostate cancer and non-tumor tissue were analyzed by miRNA microarray hybridization (miRNA array V1.0, Affymetrix). Scanned microarray intensity files were analyzed with Partek genomics suite version 6.2 (Partek incorporated). Differential expression of miRNAs was calculated by one-way analysis of variance (ANOVA). No correction for multiple testing was applied.
IJC_26064_sm_suppinfotableS2.doc84KSupporting Information Table S2 - MiRNA quantification by quantitative real-time RT-PCR. Corresponding tissue pairs of patient sets 1 (N=50) and 2 (N=26) were analyzed for the expression of miRNAs miR-375, miR-200c, miR-143, and miR-145. For the two patient sets and the combined cohort (N=76) the differential expression (fold change) was calculated as the median of differential expression of the matched tissue pairs. Significance was derived by Wilcoxon matched pairs test.
IJC_26064_sm_suppinfotableS3.doc375KSupporting Information Table S3 - Predicted target genes of deregulated miRNAs. Target prediction was performed using miRecords. A miRNA target gene had to be predicted by miRanda, Targetscan, and picTar and at least two other target prediction algorithms.
IJC_26064_sm_suppinfo.doc22KSupporting Information

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.